Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
Acker F, Chromik J, Tiedjen E, Wolf S, Vischedyk JB, Makowka P, Enßle JC, Kouidri K, Sebastian M, Steffen B, Oellerich T, Serve H, Neubauer A, Schäfer JA, Bittenbring JT. Acker F, et al. Among authors: schafer ja. Eur J Haematol. 2024 Nov;113(5):623-630. doi: 10.1111/ejh.14278. Epub 2024 Jul 18. Eur J Haematol. 2024. PMID: 39023132
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.
Tarawneh TS, Rodepeter FR, Teply-Szymanski J, Ross P, Koch V, Thölken C, Schäfer JA, Gremke N, Mack HID, Gold J, Riera-Knorrenschild J, Wilhelm C, Rinke A, Middeke M, Klemmer A, Romey M, Hattesohl A, Jesinghaus M, Görg C, Figiel J, Chung HR, Wündisch T, Neubauer A, Denkert C, Mack EKM. Tarawneh TS, et al. Among authors: schafer ja. Cancers (Basel). 2022 Sep 12;14(18):4430. doi: 10.3390/cancers14184430. Cancers (Basel). 2022. PMID: 36139590 Free PMC article.
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Konopleva MY, Röllig C, Cavenagh J, Deeren D, Girshova L, Krauter J, Martinelli G, Montesinos P, Schäfer JA, Ottmann O, Petrini M, Pigneux A, Rambaldi A, Recher C, Rodriguez-Veiga R, Taussig D, Vey N, Yoon SS, Ott M, Muehlbauer S, Beckermann BM, Catalani O, Genevray M, Mundt K, Jamois C, Fenaux P, Wei AH. Konopleva MY, et al. Among authors: schafer ja. Blood Adv. 2022 Jul 26;6(14):4147-4156. doi: 10.1182/bloodadvances.2021006303. Blood Adv. 2022. PMID: 35413116 Free PMC article. Clinical Trial.
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.
Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Bücklein V, Trenker C, Hernani R, Naumann R, Schäfer J, Blumenberg V, Schmidt C, Sohlbach K, von Bergwelt-Baildon M, Bachy E, Barba P, Subklewe M. Rejeski K, et al. Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776. Blood Adv. 2022. PMID: 35793454 Free PMC article. No abstract available.
147 results